What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?

Elisa Tassinari; Matteo Rosellini; Andrea Marchetti; Veronica Mollica; Francesco Massari

doi:10.1080/17425255.2024.2314059

What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?

Expert Opin Drug Metab Toxicol. 2024 Jan-Feb;20(1-2):5-8. doi: 10.1080/17425255.2024.2314059. Epub 2024 Feb 5.

Authors

Elisa Tassinari^{1

2}, Matteo Rosellini^{1

2}, Andrea Marchetti^{1

2}, Veronica Mollica^{1

2}, Francesco Massari^{1

2}

Affiliations

¹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
² Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.

PMID: 38299484
DOI: 10.1080/17425255.2024.2314059

No abstract available

Keywords: Adverse event; hepatitis; hepatotoxicity; hypertransaminasemia; immune checkpoints inhibitors; immune-mediated hepatotoxicity; immunotherapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological*
Chemical and Drug Induced Liver Injury* / etiology
Chemical and Drug Induced Liver Injury* / prevention & control
Drug-Related Side Effects and Adverse Reactions*
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological